Skip to content
AnalystLens

Royalty Pharma 8-K Report, Financial Results (Feb 11, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 11, 2026
Period End
February 11, 2026
Security
RPRX
In the record · 2020–202610-K610-Q208-K80

RPRX filed 6 annual reports (10-K), 20 quarterly reports (10-Q) and 80 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Impairment8-K · Dec ’22Dec ’22
  3. Material agreement8-K · Dec ’23Dec ’23
  4. Leadership change8-K · Aug ’25Aug ’25

01—Abstract

Summary

Summary of the 8-K filed February 11, 2026. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1 to this Form 8-K.

Portfolio Receipts were $874 milliona in Q4 2025, up 18% from $742 million, and $3,254 million for FY 2025, up 16% from $2,801 million. Net cash provided by operating activities was $827 million in Q4 2025 and $2,490 million for FY 2025, down 10% for the full year. Adjusted EBITDA (non-GAAP) was $2,966 million for FY 2025, up 16%, and Portfolio Cash Flow (non-GAAP) was $2,724 million, up 11%.

The company deployed $2.6 billionb of capital in 2025, including $1.2 billion of share repurchases (37 million Class A shares) and a record amount of capital returned to shareholders. It also highlighted the successful internalization of its external manager, which extinguished the management fee after May 16, 2025. Management guided 2026 Portfolio Receipts to $3,275 million to $3,425 million, excluding future transactions, with Royalty Receipts growth of 3% to 8% and interest paid of $350 million to $360 million.

The quarterly dividend was raised 7% to $0.235c per share in Q1 2026. At year-end 2025 the company had cash and cash equivalents of $619 million and total debt with principal value of $9.2 billion.

Balance sheet data show long-term debt, net of current portion, rising to $8,571 milliond from $6,615 million a year earlier. Investors will watch 2026 catalysts the release names, including pivotal study results for daraxonrasib, pelacarsen and litifilimab, along with new royalty transactions such as the up-to-$500 million Teva TEV-'408 funding agreement announced in January 2026.

02—Key points

Key Highlights

  1. Portfolio Receipts rose 18% to $874 million in Q4 2025 and 16% to $3,254 million for FY 2025.
  2. Net cash provided by operating activities was $827 million in Q4 2025 and $2,490 million for FY 2025, versus $2,769 million in FY 2024.
  3. Capital Deployment totaled $2.6 billion in 2025, including acquisitions of financial royalty assets of $1,698 million and development-stage funding payments of $452 million.
  4. Repurchased 37 million Class A ordinary shares for $1.2 billion in 2025; weighted-average diluted shares fell to 564 million from 594 million.
  5. 2026 Portfolio Receipts guidance of $3,275 million to $3,425 million, excluding future transactions; interest paid guided to $350 million to $360 million.
  6. Quarterly dividend increased 7% to $0.235 per share in Q1 2026.
  7. Year-end cash of $619 million against total debt with principal value of $9.2 billion.

03—Questions

Frequently Asked Questions

  1. What drove the growth in Royalty Receipts in Q4 2025?

    Royalty Receipts grew 17% to $856 million, primarily driven by Voranigo, Trelegy, Tremfya and the cystic fibrosis franchise, partially offset by a decline from Promacta due to U.S. generic competition launched in May 2025.

  2. Why are 2026 operating and professional costs expected to decline as a share of revenue?

    The company expects payments for operating and professional costs to be 5.5% to 6.5% of Portfolio Receipts in 2026, compared with 8.9% in 2025, primarily due to the extinguishment of the management fee following the internalization transaction completed on May 16, 2025.

  3. What royalty transactions did Royalty Pharma announce in late 2025 and early 2026?

    During 2025 the company announced new transactions of up to $4.7 billion. Recent deals include the acquisition of Evrysdi royalties from PTC Therapeutics for a $240 million upfront payment, a Nuvalent neladalkib and zidesamtinib royalty acquisition for up to $315 million, a Denali tividenofusp alfa royalty for up to $275 million, and a January 2026 Teva TEV-'408 funding agreement for up to $500 million.

  4. What 2026 catalysts does the company highlight for its development-stage pipeline?

    Management said it anticipates multiple events in 2026, including pivotal study results for daraxonrasib, pelacarsen and litifilimab, which it believes could unlock additional value.

04—Continue

← View all 8-K filings